GlassScriptPhysician profile
Emily Mccort
NPI 1538169859
$1,536.22
in general payments reported to CMS, 2019-2025
11 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $135 · 2021: $16.39 · 2022: $594 · 2023: $199 · 2024: $228 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $389.73 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $223.30 | 2019-2025 | Abilify Asimtufii |
| Alkermes, INC. | $194.95 | 2022-2024 | Lybalvi |
| Abbvie INC. | $177.33 | 2022-2023 | |
| Corium, LLC | $140.29 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.80 | 2022 | |
| Allergan, INC. | $112.86 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $105.81 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $35.56 | 2021-2022 | |
| Eisai INC. | $22.44 | 2020 | |
| Tris Pharma INC | $14.15 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Mccort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.